Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Expected outcomes of therapy
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

2 evidence topics · 2 sources

Progression-free survival in the pivotal comparison

“mPFS, as assessed by blinded independent central review, was 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy.” (opens the source at this quote in a new tab)

Overall-survival maturity

“Data for overall survival remains immature.” (opens the source at this quote in a new tab)